N/A N=1 Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab
Relapsing Polychondritis
Primary: Physician Global Assessment of Disease Activity — 21; 14; 12; 43 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
Nasal Polyps · Gastroesophageal Reflux
Primary: Presence of Reflux in Patients With Polyposis — 15 participants
Phase 2 N=20 Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Phase 2 N=41 Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline — -5.4; -15.2 percent change in mean growth rate — p=0.57
Phase 3 N=10 Rituximab in Rheumatoid Arthritis Lung Disease
Rheumatoid Arthritis · Interstitial Pneumonia
Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants
Phase 2 N=24 Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis
Chronic Rhinosinusitis (Diagnosis) · Nasal Polyps · Eosinophilia
Primary: Change in Nasal Polyp Score — .9; .3 score on a scale
Phase 3 N=42 Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria
Arthritis, Reactive · Reiter Disease
Primary: Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment. — 10; 7; 3 participants — p=0.01
Phase 2 N=10 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
Phase 3 N=100 Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps
Chronic Sinusitis · Nasal Polyps
Primary: Nasal Obstruction/Congestion Score — 3.62; 3.30; 2.31; 2.62 units on a scale — p=0.1365
Phase 2 N=26 A Pilot Study of KPL-914 in Recurrent Pericarditis
Recurrent Pericarditis
Primary: Parts 1, 2 and 4: Pretreatment C-Reactive Protein (CRP) Levels — 5.921; 0.645; 4.455; 5.156 mg/dL
Phase 3 N=197 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Vasculitis · Wegener's Granulomatosis · Microscopic Polyangiitis
Primary: Disease Remission — 63; 52 Participants — p=<0.001
Phase 3 N=86 Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
Recurrent Pericarditis
Primary: Time to Pericarditis Recurrence in the RW Period — NA; 8.6 weeks — p=<0.0001
Phase 4 N=19 Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale
Phase 3 N=138 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
Nasal Polyps · Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) at Week 24 — 0.06; -1.08 Score on a scale — p=<0.0001
Early Phase 1 N=49 Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis
Uveitis
Primary: Change in Mean Number of Uveitis Relapses Per Patient Between the 12 Month Study Period Compared to Baseline — 0.35; 0.58 Relapses Per Patient
Phase 2 N=21 Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
Recurrent Respiratory Papillomatosis
Primary: Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST — 21 Participants
Phase 3 N=407 Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Nasal Polyps
Primary: Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 52 — 0.0; -1.0 Scores on a scale — p=<0.001
Phase 2 N=12 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease
Sensorineural Hearing Loss · Autoimmune Inner Ear Disease
Primary: To Assess the Potential Efficacy of Anakinra in Improving Hearing Thresholds in Corticosteroid-resistant Patients With Autoimmune Inner Ear Disease — 7 responders
Phase 2 N=3 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
Phase 2 N=20 Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
Polypoidal Choroidal Vasculopathy
Primary: Commonly Reported and Notable Adverse Events — 1; 2; 2; 3 participants
Phase 3 N=127 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps
Nasal Polyps · Chronic Rhinosinusitis
Primary: Change From Baseline in Nasal Polyp Score (NPS) at Week 24 — -0.31; -0.90 Score on a scale — p=0.0140
N/A N=24 Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps
Sinusitis
Primary: Sinonasal Outcome Test (SNOT 20) — 50.33; 53.14; 37 Score out of total 100
Phase 3 N=408 Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
Chronic Rhinosinusitis With Nasal Polyps
Primary: Change From Baseline in Total Nasal Polyp Score at Week 52 — -2.458; -0.380 Score — p=<.0001
Phase 2 N=15 Baricitinib in Relapsing Giant Cell Arteritis
Arteritis, Giant Cell
Primary: Adverse Events — 93 percentage of subjects
Phase 2 N=51 Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Primary: %Survival — 44; 7 percentage of participants
Phase 3 N=170 Rituximab Vasculitis Maintenance Study
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Microscopic Polyangiitis · Wegener Granulomatosis
Primary: Relapse-free Survival — 38; 60; 13; 32 participants
Phase 3 N=196 Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps. — -2.13; -2.06 score on a scale
Phase 2 N=13 Avelumab for People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Juvenile Laryngeal Papilloma · Laryngeal Papilloma, Recurrent
Primary: Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated…
N/A N=17 Effects of Radiofrequency Ablation of Posterior Nasal Nerves on Inflammatory Cytokines, Peak Nasal Inspiratory Flow, and Nasal Blood Flow in Patients With Chronic Rhinitis
Chronic Rhinitis
Primary: Nasal Congestion as Assessed by the Peak Nasal Inspiratory Flow (PNIF) — 90 Liters Per Minute
Phase 2 N=20 Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Primary: Ratio to Baseline in Peripheral Blood Eosinophil Counts After 6 Months of Treatment — 0.06 ratio to baseline — p=< 0.001